Strs Ohio trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 194,815 shares of the medical research company’s stock after selling 4,553 shares during the period. Strs Ohio’s holdings in Amgen were worth $56,110,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Briaud Financial Planning Inc purchased a new stake in Amgen during the third quarter valued at about $26,000. OFI Invest Asset Management purchased a new stake in shares of Amgen during the third quarter worth about $26,000. Planned Solutions Inc. purchased a new stake in shares of Amgen during the fourth quarter worth about $30,000. Providence Capital Advisors LLC purchased a new stake in shares of Amgen during the third quarter worth about $30,000. Finally, Hartford Financial Management Inc. boosted its holdings in shares of Amgen by 56.9% during the fourth quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock worth $33,000 after purchasing an additional 41 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Trading Up 0.4 %
NASDAQ:AMGN opened at $268.24 on Monday. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a market capitalization of $143.76 billion, a price-to-earnings ratio of 21.40, a price-to-earnings-growth ratio of 2.53 and a beta of 0.58. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The business has a fifty day moving average price of $280.76 and a 200-day moving average price of $281.55.
Amgen Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.36%. Amgen’s payout ratio is presently 72.06%.
Analysts Set New Price Targets
AMGN has been the subject of a number of analyst reports. BMO Capital Markets upgraded shares of Amgen from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $286.00 to $326.00 in a report on Tuesday, December 19th. Truist Financial reissued a “buy” rating and issued a $320.00 price target on shares of Amgen in a research note on Friday. The Goldman Sachs Group increased their price target on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Morgan Stanley decreased their price target on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 7th. Finally, Raymond James began coverage on shares of Amgen in a research note on Thursday, March 28th. They set a “market perform” rating for the company. Ten research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $295.30.
View Our Latest Research Report on AMGN
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- How to Use High Beta Stocks to Maximize Your Investing Profits
- When Will the Next Bull Market Be?
- How to Effectively Use the MarketBeat Ratings Screener
- Kraft Heinz Stock Comprehensive Analysis for 2024
- Do ETFs Pay Dividends? What You Need to Know
- NVIDIA Stock Analysis: Insights and Predictions for Investors
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.